Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-719 Phase 2b trial for prevention of acute kidney injury in high-risk cardiac surgery
2012-003942-33Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of modimelanotide in acute kidney failure (AKF) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Incidence of acute kidney injury (AKI) by AKIN criteria. Started Apr 2013; status: completed.
02
Drugs
modimelanotide
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2012-003942-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003942-33.